Home > Insider Trading > Filing (0001140361-18-045048)

Filing Details

Accession Number:: 0001140361-18-045048
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-12-12 21:41:38
Reporting Period:: 2018-12-10

Accepted Time:: 2018-12-12 21:41:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1661181	Organogenesis Holdings Inc.	ORGO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1664173	Avista Capital Partners (Offshore) Iv, L.p.	C/O Avista Capital Partners 65 E. 55Th Street, 18Th Floor New York NY 10022	No	No	No	No
1664176	Avista Capital Partners Iv, L.p.	C/O Avista Capital Partners 65 E. 55Th Street, 18Th Floor New York NY 10022	No	No	No	No
1761175	Avista Capital Managing Member Iv, Llc	C/O Avista Healthcare Public Acquisition Corp., 65 East 55Th Street, 18Th Floor New York NY 10022	No	No	No	No
1761195	Avista Capital Partners Iv Gp, L.p.	C/O Avista Capital Partners 65 East 55Th Street, 18Th Floor New York NY 10022	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2018-12-10	6,538,732	$0.00	15,561,473	No	4	P	Indirect	See Notes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Notes

Footnotes

This statement is being filed by the following Reporting Persons: Avista Capital Partners IV, L.P. ("Fund IV"), Avista Capital Partners (Offshore) IV, L.P. ("Offshore Fund IV"), Avista Capital Partners IV GP, L.P. ("Fund IV GP"), which is the general partner of Fund IV and Offshore Fund IV; and Avista Capital Managing Member IV, LLC, which is the general partner of Fund IV GP.
Represents 3,278,154 shares of Class A common stock received by Fund IV and 3,260,578 shares of Class A common stock received by Offshore Fund IV, in each case, at an exchange ratio of 2.03 shares of the Issuer's Class A common stock for each share of common stock of Organogenesis Inc. in connection with the consummation of the business combination pursuant to that certain Agreement and Plan of Merger, dated as of August 17, 2018, by and among Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis Inc.
Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.